Trials / Recruiting
RecruitingNCT07300241
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Neomorph, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study of NEO-811 for subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.
Conditions
- Clear Cell Renal Cell Carcinoma
- Renal Cell Carcinoma
- RCC
- Clear Cell Renal Cell Carcinoma Metastatic
- ccRCC
- VHL-Associated Clear Cell Renal Cell Carcinoma
- VHL-Associated Renal Cell Carcinoma
- Kidney Cancer Metastatic
- Kidney Cancers
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NEO-811 | NEO-811 |
Timeline
- Start date
- 2025-12-19
- Primary completion
- 2027-01-01
- Completion
- 2027-09-01
- First posted
- 2025-12-23
- Last updated
- 2026-03-11
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07300241. Inclusion in this directory is not an endorsement.